Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03361501 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
A Phase 3 study, sponsored by Grace Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 278
- Enrollment target
NCT03361501 is a Phase 3 study that has completed, run by Grace Therapeutics. The registered enrollment target is 278 participants.
The verdict
NCT03361501, a Phase 3 study, has completed, sponsored by Grace Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 278 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the efficacy of CaPre 4 g daily, compared to placebo, in lowering fasting TG levels in subjects with fasting TG levels ≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L) after 12 weeks of treatment. Approximately 615 subjects will be screened to obtain 245 randomized subjects following a treatment allocation ratio of 2.5:1 (CaPre:placebo).
Interventions
- DRUG Placebo
- DRUG CaPre
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03361501
The ClinicalTrials.gov registry entry for NCT03361501 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grace Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03361501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03361501 about?
NCT03361501 is a clinical study titled "A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)". The primary objective of this study is to determine the efficacy of CaPre 4 g daily, compared to placebo, in lowering fasting TG levels in subjects with fasting TG levels ≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L) after 12 weeks of treatment. Approximately 615 subjects will be screen...
What is the current status of trial NCT03361501?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 278 participants. The study started on 2018-02-01. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT03361501?
The interventions under investigation include: Placebo (DRUG), CaPre (DRUG).
Who is sponsoring clinical trial NCT03361501?
This trial is sponsored by Grace Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.